The antibiotic vancomycin is failing.
Not because the molecule itself is broken. But because bacteria are evolving around it. Vancomycin-resistant Enterococcus faecium (VRE) doesn’t care about the drug’s reputation. It ignores it.
This is the superbug crisis. Not in abstract. But in rooms. In ICUs. In nursing homes.
When frontline antibiotics lose their bite, routine procedures turn deadly. Surgery. Cancer chemo. Any time your body needs a chemical shield against infection, you’re gambling if the shield no longer exists.
So, what’s the move? Do we spend decades and billions searching for entirely new antibiotics? That’s the old game. The new strategy is smarter.
You don’t need a new sword if you can just sharpen the one you have.
The Adjuvant Approach
Enter the adjuvant.
Not the supplement kind. A chemical partner.
The idea is simple but hard to pull off. Pair an existing, trusted antibiotic with a molecule that doesn’t kill bacteria at all. Instead, that partner disables the bacteria’s defense mechanisms. It takes away the shield so the antibiotic can do its job again.
It’s a hack. A backdoor entry into bacterial immunity.
This is exactly what researchers at Cold Spring Harbor Laboratory (CSHL), led by John Moses, have done. They didn’t start out trying to cure MRSA. They were doing basic chemistry.
From Reaction Library to Life Saver
Moses’s lab develops chemical reactions. Fast ones. Efficient ones.
They call it diversity-oriented clicking (DOC). It’s a method for assembling complex molecular structures quickly. Think of it like a high-speed factory line for test tubes.
The output? A library.
Over 150 compounds. Diverse structures. Ready for biological testing.
This library wasn’t built for antibiotics. It was built to expand the range of molecules available for research. Basic chemistry. Pure and simple.
But basic chemistry has a habit of surprising you.
A collaboration with Scripps Research took this library and ran it against the superbug problem. Specifically, against vancomycin-resistant E. faecium.
The goal was clear. See if any of these random molecules could make vancomycin lethal again.
They did.
Blocking SagA
The culprit behind the resistance was identified as an enzyme. Secreted antigen A. SagA for short.
This enzyme helps bacteria remodel their cell walls. It’s part of the peptidoglycan process. Basically, it’s how the bug patches itself up against attacks. If you stop SagA, the bug gets weaker.
Moses and Howard Hang’s group at Scripps found a small molecule that blocks SagA.
They called it pghi-4.
First identified in Moses’s lab back in 2020, pghi-4 looked promising in isolation. But it wasn’t a killer. It didn’t touch the bacteria directly.
Then they added vancomycin to the mix.
The result was immediate.
Pghi-4 inhibited SagA. The bacteria’s defense crumbled. Vancomycin regained its killing power.
Resistant E. faecium became susceptible again.
Not by Design
This wasn’t a targeted drug discovery project.
You didn’t see researchers in lab coats staring at SagA’s crystal structure, designing a lock for its key. That’s not how this happened.
It was a side effect of efficient chemistry.
“We were constantly refining our reaction methods,” Moses explained. The process kept the molecular library updated. Added new shapes. New possibilities.
Collaborators just took what was there and tested it against real-world threats.
“This discovery came from fundamental chemical research,” Moses said. “Reaction development led to the discovery… This is a process we’re constantly refining.”
It’s a philosophy of chemistry. Accelerate drug discovery by building better, more intelligent reactions. Don’t guess. Build. Test. Repeat.
Why This Matters
The implications stretch beyond one strain of bacteria.
The library used to find pghi-4 is now open for collaborators to use. The method is repeatable. The chemistry is robust.
This opens the door for similar efforts against other resistant pathogens.
Tuberculosis?
Mycobacterium tuberculosis strains that ignore standard drugs could be next. The same approach could work. Find the enzyme. Block it. Restore the antibiotic.
We are running out of time on the traditional model of finding new antibiotics from scratch. Evolution is faster than synthesis.
But re-purposing? Reviving?
That might be the edge we need.
A compound born from basic chemical research just proved that established medicines aren’t obsolete. They’re just locked away.
And we finally found the key.
Reference:
“Genetic and pharmacological inactivation of pePTidoglycan remodeling increases antibiotic susceptibility to vancomycin-resistant Enterococcus faeccium” by Kyong T. Fam et al. Nature Communications, June 16, 2026. DOI: 10.1038-s41467-0226-740557-1
